March 20, 2017: Jazz Pharmaceuticals announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints in the TONES 3 study at the 300 mg, 150 mg, 75 mg and 37.5 mg dose arms (Read More….)
March 8, 2017: Teligent announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Gel, 0.05%. This is Teligent’s second approval for 2017, and its thirteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.
Based on recent QuintilesIMS Health (Read More….)
February 28, 2017: Endo International reports Q4 EPS of $1.77 versus the $1.63 estimate. Revenue also beat coming in at $1.24 billion versus the $1.15 billion estimate.
CEO Paul Campanelli said, “Endo’s core assets include a Generics business, which is the fourth largest in the U.S. based on sales, that possesses a growing sterile (Read More….)
February 6, 2017: Mylan stock got my attention today because the stock climbed on the news that Mylan has to pay $96.5 million in settlement of the Provigil antitrust class action suit. The settlement covers allegations that Mylan delayed launching its generic version of Cephalon narcolepsy drug Provigil in exchange for payment from Cephalon. The (Read More….)
February 5, 2017: Sell Teva Pharmaceutical for a -1.54% loss. Sorry folks but better to get out for a small loss as not sure how big of penalties we’re looking at IF Teva is found guilty of actually doing what the State of California is saying they did but I’m thinking possibly hundreds of millions. (Read More….)
February 01, 2017: Lannett Company reports Q2 EPS of $0.92 versus the $0.83 estimate. Revenue also beat coming in at $170.9 million versus the $169 million estimate.
The CEO said, “Higher sales across a number of products and the addition of KU’s operations were key drivers to the 35% increase in our fiscal 2017 (Read More….)
January 17, 2017: Avondale Partners raised McKesson to Market Outperform from Market Perform.
January 17, 2017: McKesson agrees to $150 million settlement with DOJ over failure to report suspicious orders of drugs. The nationwide settlement requires McKesson to suspend sales of controlled substances from distribution centers in Colorado, Ohio, Michigan and Florida for multiple years. (Read More….)
January 12, 2017: CVS announced that a low-cost epinephrine auto-injector option, the authorized generic for Adrenaclick manufactured by Impax Laboratories (IPXL), is available at all CVS Pharmacy locations at a cash price of $109.99 for a two-pack. This compares to a cash price of $649.99 for EpiPenand $339.99 for the authorized generic for EpiPen.
The (Read More….)
February 28, 2016: Novartis announced that the FDA has approved Afinitor for the treatment of some tumors. The FDA has approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival (PFS) in a multicenter, randomized (2:1), placebo-controlled trial of everolimus 10 mg orally once daily plus best supportive care (BSC) to placebo plus BSC. (Read More….)
For the week the S&P 500 fell -1.9%, the DJIA fell -1.5%, and the Nasdaq plunged -2.8%. Last week the VIX shot back above 20 to trade at levels not seen since the June Brexit vote. The S&P extended its longest losing streak since 1980 with its ninth consecutive decline on Friday.
Oil was (Read More….)
Pharmaceutical drug pricing is all over the mainstream financial media right now. Let’s examine the macroeconomics of what is happening.
The demand for pharmaceutical drugs is inelastic. People that need a pharmaceutical drug prescribed by their doctor will demand that drug regardless of price. As the price of the drug goes up, demand mostly stays (Read More….)